Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

Organon CEO pins high hopes on upcoming Humira biosimilar launch
Fierce Pharma
Thu, 02/17/22 - 11:18 pm
Tags:
Organon, biosimilar, Humira, drug launches, AbbVie
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’
Fierce Pharma
Fri, 02/11/22 - 11:46 am
Tags:
AbbVie, pharma marketing, migraines, Qulipta, television ads, DTC ads
AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec
Fierce Pharma
Thu, 02/10/22 - 08:02 pm
Tags:
AbbVie, Biohaven, migraines, Qulipta, Nurtec ODT
AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat
Fierce Pharma
Wed, 02/2/22 - 11:50 pm
Tags:
AbbVie, earnings, Restasis, FDA, generics
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
Endpoints
Wed, 02/2/22 - 11:46 pm
Tags:
AbbVie, earnings, Rick Gonzalez, Skyrizi, Rinvoq
AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger
Fierce Pharma
Wed, 01/26/22 - 11:00 am
Tags:
AbbVie, antitrust, Bystolic, generics, Allergan
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
Yahoo/Zacks.com
Mon, 01/24/22 - 11:30 pm
Tags:
AbbVie, Skyrizi, FDA, psoriatic arthritis
What This FDA News Could Mean for AbbVie's Stock
Motley Fool
Mon, 01/24/22 - 10:10 am
Tags:
AbbVie, Rinvoq, FDA
3 Clinical Trials to Watch in the First Half of 2022
Motley Fool
Sat, 01/22/22 - 02:20 pm
Tags:
clinical trials, Pfizer, Arena Pharmaceuticals, etrasimod, Roche, Alzheimer's disease, gantenerumab, AbbVie, cystic fibrosis
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
Fierce Pharma
Thu, 01/13/22 - 11:00 am
Tags:
AbbVie, Rinvoq, Skyrizi, JPMHC 2022
AbbVie seeks approval for upadacitinib to treat nr-axSpA
Pharmaceutical Business Review
Mon, 01/10/22 - 11:29 am
Tags:
AbbVie, FDA, EMA, upadacatinib, nr-axSpA, non-radiographic axial spondyloarthritis
FDA grants breakthrough designation to AbbVie’s Teliso-V for NSCLC treatment
Pharmaceutical Business Review
Wed, 01/5/22 - 10:33 am
Tags:
FDA, AbbVie, Teliso-V, telisotuzumab vedotin, non-small cell lung cancer
10 clinical trials to watch in the first half of 2022
BioPharma Dive
Mon, 01/3/22 - 10:46 am
Tags:
clinical trials, Pfizer, Arena Pharmaceuticals, etrasimod, Sanofi, GSK, vaccines, COVID-19, Roche, gantenerumab, AbbVie, Gilead Sciences, Trodelvy, Karuna Therapeutics, KarXT, Intercept Pharma, obeticholic acid, Allogene, ALLO-501a
Could This FDA Approval Create a Blockbuster Drug for AbbVie?
Motley Fool
Sun, 01/2/22 - 11:36 pm
Tags:
AbbVie, Rinvoq, FDA, psoriatic arthritis
Teva suffers trial loss in New York's landmark opioid case
Fierce Pharma
Thu, 12/30/21 - 08:03 pm
Tags:
Teva Pharmaceutical, AbbVie, JNJ, New York, legal, opioids, opioid crisis
What AbbVie's Recent Drug News Means for Shareholders
Motley Fool
Tue, 12/28/21 - 10:57 am
Tags:
AbbVie, Skyrizi, Crohn’s disease, Europe
What to Make of the FDA's Latest Warning to AbbVie and Pfizer
Motley Fool
Sat, 12/18/21 - 10:56 pm
Tags:
FDA, AbbVie, Pfizer, Rinvoq, Xeljanz, JAK inhibitors
Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial
Endpoints
Wed, 12/15/21 - 11:49 pm
Tags:
Idera Pharmaceuticals, AbbVie, melanoma, clinical trials, tilsotolimod
Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change
Endpoints
Wed, 12/15/21 - 10:52 am
Tags:
Pfizer, AbbVie, Xeljanz, Rinvoq, FDA, JAK inhibitors
AbbVie prices first presbyopia drug Vuity at $80 per month
Pharmaforum
Fri, 12/10/21 - 10:48 am
Tags:
AbbVie, Vuity, presbyopia

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.